← brief for 2026-10-08 · Slowing decline

Sofosbuvir/Daclatasvir versus Grazoprevir/Elbasvir in Patients with Chronic Hepatitis C on Haemodialysis: A Multicentre, Single-Blind, Randomised Controlled Trial

Article B Peer reviewed Small trial

Key takeaways

People on dialysis with hepatitis C were given one of two drug combinations. The study compared a newer, cheaper option against a standard, expensive one. Both drugs worked well to clear the virus. The cheaper option was just as safe and effective. This gives doctors a better, less costly choice for treating this infection.

Who did this work

Andri Sanityoso Sulaiman (Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo) · Pringgodigdo Nugroho (Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo) · Muhammad Begawan Bestari (Dr. Hasan Sadikin General Hospital) · Afiatin Afiatin (Dr. Hasan Sadikin General Hospital) · Fardhah Akil · Akhyar Albaar · Hery Djagat Purnomo (Dr. Kariadi Hospital) · Dwi Lestari (Dr. Kariadi Hospital) · Triyanta Yuli Pramana (Dr. Kariadi Hospital) · Agung Susanto · Desti Rachmani · Lawrence Ho Khek-Yu (National University of Singapore)

Source

Article · OpenAlex, CKD works · 2026-10-07
https://openalex.org/W7220887758